Major bleeding (MB) events are feared and potentially fatal complications of anticoagulant treatment in patients with venous thromboembolism (VTE). Even though several clinical risk factors are associated with MB risk, the predictive power of currently available risk assessment models remain limited for VTE. The aim of this thesis was to identify biomarkers of MB risk during the first year after an ...